Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients

Tissue Antigens

Volumn 83, Issue 1, 2014, Pages 45-48

  Nozawa, Y ^a   Umemura, T ^a   Katsuyama, Y ^b   Shibata, S ^a   Kimura, T ^a   Morita, S ^a   Joshita, S ^a   Komatsu, M ^a   Matsumoto, A ^a   Yoshizawa, K ^a   Ota, M ^a   Tanaka, E ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

hepatitis C virus; IL28B; interferon 4; Pegylated interferon

Indexed keywords

INTERFERON; INTERFERON LAMBDA 4; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; HEPATITIS C; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL CLEARANCE;

HEPATITIS C VIRUS; IL28B; INTERFERON-Λ 4; PEGYLATED INTERFERON;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890748447     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12264     Document Type: Article

References (18)

1. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989: 321: 1494-500.
2. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990: 12: 671-5.
3. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009: 44 (Suppl 19): 102-7.
4. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012: 56: 78-84.
5. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010: 139: 1865-76.
6. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009: 41: 1105-9.
7. Ito K, Higami K, Masaki N et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011: 49: 1853-60.
8. Umemura T, Joshita S, Yoneda S et al. Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther 2011: 16: 1073-80.
9. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013: 45: 164-71.
10. Booth D, George J. Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C. Nat Genet 2013: 45: 119-20.
11. Umemura T, Wang RY, Schechterly C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006: 43: 91-9.
12. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007: 46: 463-71.
13. Yoneda S, Umemura T, Katsuyama Y et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011: 203: 1087-95.
14. Umemura T, Joshita S, Ichijo T et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 2012: 55: 506-11.
15. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002: 296: 2225-9.
16. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005: 21: 263-5.
17. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009: 461: 798-801.
18. Bibert S, Roger T, Calandra T et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013: 210: 1109-16.